Nifty
Sensex
:
:
11050.25
37388.66
244.70 (2.26%)
835.06 (2.28%)

Chemicals

Rating :
70/99

BSE: 532834 | NSE: CAMLINFINE

102.15
25-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  99.70
  •  102.15
  •  95.30
  •  97.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  651187
  •  655.21
  •  102.15
  •  33.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,241.03
  • 41.16
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,701.81
  • N/A
  • 2.93

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 22.74%
  • 10.31%
  • 35.77%
  • FII
  • DII
  • Others
  • 1.16%
  • 17.49%
  • 12.53%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.84
  • 16.48
  • 13.34

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.15
  • 8.05
  • 55.97

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.15
  • -3.28
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.40
  • 17.75
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.44
  • 3.37
  • 2.41

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.46
  • 36.81
  • 51.53

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
305.74
260.12
17.54%
292.87
268.03
9.27%
273.88
241.40
13.45%
222.28
201.34
10.40%
Expenses
254.67
224.57
13.40%
258.58
251.23
2.93%
244.33
228.05
7.14%
192.26
184.12
4.42%
EBITDA
51.08
35.56
43.64%
34.29
16.80
104.11%
29.55
13.35
121.35%
30.01
17.22
74.27%
EBIDTM
16.71%
13.67%
11.71%
6.27%
10.79%
5.53%
13.50%
8.55%
Other Income
0.67
0.65
3.08%
2.77
4.60
-39.78%
1.38
0.84
64.29%
0.64
9.88
-93.52%
Interest
10.76
5.93
81.45%
15.23
7.37
106.65%
8.28
8.98
-7.80%
14.42
9.48
52.11%
Depreciation
9.48
7.59
24.90%
9.13
7.31
24.90%
8.41
6.80
23.68%
7.68
7.65
0.39%
PBT
31.51
22.68
38.93%
12.71
6.72
89.14%
14.25
-1.60
-
8.56
9.97
-14.14%
Tax
10.95
6.25
75.20%
10.65
0.36
2,858.33%
10.43
-0.81
-
1.04
8.04
-87.06%
PAT
20.56
16.43
25.14%
2.05
6.36
-67.77%
3.83
-0.79
-
7.52
1.93
289.64%
PATM
6.72%
6.32%
0.70%
2.37%
1.40%
-0.33%
3.38%
0.96%
EPS
1.69
1.35
25.19%
0.17
0.52
-67.31%
0.32
-0.06
-
0.62
0.16
287.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,094.77
1,049.15
892.17
720.60
533.93
489.34
558.27
508.67
373.62
335.25
171.67
Net Sales Growth
12.76%
17.60%
23.81%
34.96%
9.11%
-12.35%
9.75%
36.15%
11.45%
95.29%
 
Cost Of Goods Sold
561.79
533.78
474.80
422.44
260.51
203.10
270.49
275.73
164.64
167.52
113.41
Gross Profit
532.98
515.37
417.36
298.16
273.42
286.24
287.78
232.94
208.98
167.73
58.26
GP Margin
48.68%
49.12%
46.78%
41.38%
51.21%
58.50%
51.55%
45.79%
55.93%
50.03%
33.94%
Total Expenditure
949.84
913.94
819.26
705.95
503.23
397.55
474.10
449.20
327.56
306.22
156.13
Power & Fuel Cost
-
76.38
80.42
61.43
46.35
47.43
58.00
51.43
57.06
55.65
8.71
% Of Sales
-
7.28%
9.01%
8.52%
8.68%
9.69%
10.39%
10.11%
15.27%
16.60%
5.07%
Employee Cost
-
99.71
87.89
72.87
61.09
40.05
40.58
34.37
30.10
23.69
10.41
% Of Sales
-
9.50%
9.85%
10.11%
11.44%
8.18%
7.27%
6.76%
8.06%
7.07%
6.06%
Manufacturing Exp.
-
50.73
53.49
34.70
31.04
37.04
35.06
26.59
24.03
12.88
5.57
% Of Sales
-
4.84%
6.00%
4.82%
5.81%
7.57%
6.28%
5.23%
6.43%
3.84%
3.24%
General & Admin Exp.
-
50.25
44.15
36.86
38.28
24.72
21.21
17.36
17.74
11.76
6.97
% Of Sales
-
4.79%
4.95%
5.12%
7.17%
5.05%
3.80%
3.41%
4.75%
3.51%
4.06%
Selling & Distn. Exp.
-
50.02
42.61
39.48
33.48
25.33
20.17
17.78
15.00
6.73
6.37
% Of Sales
-
4.77%
4.78%
5.48%
6.27%
5.18%
3.61%
3.50%
4.01%
2.01%
3.71%
Miscellaneous Exp.
-
53.06
35.91
38.17
32.48
19.88
28.58
25.93
18.99
27.99
6.37
% Of Sales
-
5.06%
4.03%
5.30%
6.08%
4.06%
5.12%
5.10%
5.08%
8.35%
2.73%
EBITDA
144.93
135.21
72.91
14.65
30.70
91.79
84.17
59.47
46.06
29.03
15.54
EBITDA Margin
13.24%
12.89%
8.17%
2.03%
5.75%
18.76%
15.08%
11.69%
12.33%
8.66%
9.05%
Other Income
5.46
3.43
13.79
12.91
15.65
4.27
8.38
11.84
11.16
11.84
1.80
Interest
48.69
47.63
40.95
31.80
30.58
24.44
23.82
24.66
20.11
16.69
9.17
Depreciation
34.70
32.80
28.99
26.65
21.80
17.06
16.25
11.79
13.61
13.51
5.65
PBT
67.03
58.20
16.75
-30.90
-6.03
54.57
52.48
34.86
23.51
10.67
2.52
Tax
33.07
28.37
13.69
-6.75
-1.58
14.20
-2.21
6.13
8.38
6.94
1.76
Tax Rate
49.34%
48.75%
81.73%
21.84%
26.20%
28.39%
-4.18%
17.58%
35.64%
64.14%
19.21%
PAT
33.96
30.32
0.63
-29.81
-11.20
35.82
55.04
28.74
15.12
3.88
7.40
PAT before Minority Interest
30.15
29.83
3.06
-24.14
-4.46
35.82
55.04
28.74
15.12
3.88
7.40
Minority Interest
-3.81
0.49
-2.43
-5.67
-6.74
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
3.10%
2.89%
0.07%
-4.14%
-2.10%
7.32%
9.86%
5.65%
4.05%
1.16%
4.31%
PAT Growth
41.91%
4,712.70%
-
-
-
-34.92%
91.51%
90.08%
289.69%
-47.57%
 
EPS
2.80
2.50
0.05
-2.46
-0.92
2.95
4.54
2.37
1.25
0.32
0.61

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
403.14
370.88
371.16
212.58
176.22
134.87
93.30
65.38
52.91
46.45
Share Capital
12.13
12.13
12.12
10.37
9.67
9.59
9.44
9.39
9.36
9.31
Total Reserves
390.57
336.37
336.62
200.53
166.55
125.19
83.66
55.90
43.45
37.06
Non-Current Liabilities
185.44
154.88
72.63
32.51
11.69
16.84
25.47
40.82
36.29
42.94
Secured Loans
176.24
189.02
104.63
47.51
21.45
28.06
28.52
30.72
26.02
39.95
Unsecured Loans
35.27
4.62
5.61
3.81
0.00
0.00
0.00
6.95
6.97
0.06
Long Term Provisions
2.85
2.37
1.96
2.14
1.85
1.47
0.98
0.00
0.00
0.00
Current Liabilities
547.83
460.39
470.91
385.72
279.94
261.53
245.88
263.28
196.40
94.91
Trade Payables
173.72
164.61
177.79
78.40
95.31
106.55
100.01
157.47
87.22
59.53
Other Current Liabilities
81.51
43.92
39.04
27.45
27.40
19.50
27.73
13.74
11.29
5.54
Short Term Borrowings
278.07
244.34
246.79
269.90
145.70
120.95
104.01
79.50
88.53
23.37
Short Term Provisions
14.53
7.52
7.29
9.97
11.53
14.53
14.13
12.57
9.36
6.46
Total Liabilities
1,193.38
1,045.55
976.92
648.42
467.85
413.24
364.65
369.48
285.60
184.30
Net Block
303.71
270.37
276.03
198.81
140.27
106.43
83.15
83.28
73.82
68.85
Gross Block
434.03
357.04
340.26
211.63
359.66
295.11
283.15
251.04
226.08
212.01
Accumulated Depreciation
130.32
86.67
64.24
12.82
219.38
188.69
199.99
167.76
152.27
143.16
Non Current Assets
518.42
373.07
311.37
229.03
168.13
114.54
107.90
86.28
78.66
74.55
Capital Work in Progress
178.78
59.00
13.62
7.62
25.06
2.82
22.08
0.76
2.23
3.30
Non Current Investment
9.43
9.35
9.41
9.24
1.09
1.09
1.21
1.23
1.24
1.22
Long Term Loans & Adv.
24.84
32.06
11.31
7.73
1.70
4.21
1.46
1.00
1.37
1.17
Other Non Current Assets
1.65
2.29
1.01
5.62
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
674.96
672.48
665.55
419.40
299.72
298.69
256.75
283.20
206.94
109.76
Current Investments
0.00
3.25
108.08
11.70
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
298.15
285.41
239.02
197.80
173.32
136.38
109.20
149.00
84.36
33.12
Sundry Debtors
252.80
209.32
205.35
144.89
75.48
113.42
101.32
87.06
90.17
50.33
Cash & Bank
64.79
103.44
48.08
31.24
18.90
19.26
15.80
25.74
10.23
13.13
Other Current Assets
59.22
20.99
14.10
13.00
32.03
29.63
30.42
21.39
22.18
13.18
Short Term Loans & Adv.
39.47
50.06
50.92
20.77
20.16
14.87
18.49
19.79
21.35
12.28
Net Current Assets
127.12
212.09
194.64
33.68
19.78
37.16
10.87
19.92
10.54
14.85
Total Assets
1,193.38
1,045.55
976.92
648.43
467.85
413.23
364.65
369.48
285.60
184.31

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
86.02
-9.00
-15.41
-8.69
71.57
46.26
26.74
55.61
-31.86
4.18
PBT
58.20
16.75
-30.90
-6.03
50.02
52.48
34.86
23.51
10.67
2.52
Adjustment
86.49
70.35
40.90
46.70
48.89
47.26
40.28
32.66
26.51
14.74
Changes in Working Capital
-40.76
-79.88
-15.27
-39.00
-15.14
-42.60
-38.73
5.83
-63.80
-11.18
Cash after chg. in Working capital
103.94
7.22
-5.27
1.67
83.77
57.14
36.41
62.00
-26.62
6.09
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-17.92
-16.22
-10.14
-10.36
-12.20
-10.88
-9.67
-6.39
-5.25
-1.91
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-90.12
-1.94
-148.59
-83.14
-65.67
-26.28
-32.16
-18.66
-9.21
-17.46
Net Fixed Assets
-153.66
-67.82
-7.46
59.18
-37.27
-23.68
-1.87
-12.66
-13.00
-10.18
Net Investments
-5.05
79.12
-104.14
-39.31
-2.13
-0.77
-2.48
0.00
0.15
1.92
Others
68.59
-13.24
-36.99
-103.01
-26.27
-1.83
-27.81
-6.00
3.64
-9.20
Cash from Financing Activity
3.25
25.67
181.82
90.92
-6.87
-15.48
-6.29
-21.44
38.17
23.03
Net Cash Inflow / Outflow
-0.85
14.74
17.82
-0.92
-0.97
4.49
-11.71
15.51
-2.90
9.75
Opening Cash & Equivalents
53.21
38.48
20.65
8.03
8.99
4.50
16.21
10.23
13.13
3.38
Closing Cash & Equivalent
52.37
53.21
38.48
20.65
8.03
8.99
4.50
25.74
10.23
13.13

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
33.21
28.74
28.77
20.34
18.23
14.06
9.86
6.95
5.64
4.98
ROA
2.66%
0.30%
-2.97%
-0.80%
8.13%
14.15%
7.83%
4.62%
1.65%
4.87%
ROE
7.94%
0.88%
-8.63%
-2.30%
23.04%
48.31%
36.29%
25.61%
7.82%
19.64%
ROCE
12.02%
7.32%
0.14%
5.45%
22.86%
28.50%
27.41%
23.65%
18.81%
19.26%
Fixed Asset Turnover
2.65
2.56
2.62
1.91
1.54
1.97
1.94
1.60
1.55
1.27
Receivable days
80.39
84.82
88.44
73.54
68.37
68.69
66.48
84.48
75.55
97.40
Inventory Days
101.51
107.28
110.30
123.85
112.09
78.55
91.12
111.24
63.17
62.28
Payable days
72.27
76.81
73.54
64.72
89.70
89.36
114.87
132.61
84.56
129.85
Cash Conversion Cycle
109.63
115.30
125.19
132.67
90.76
57.88
42.72
63.10
54.15
29.83
Total Debt/Equity
1.31
1.32
1.07
1.57
1.02
1.19
1.61
1.93
2.36
1.47
Interest Cover
2.22
1.41
0.03
0.80
3.05
3.22
2.41
2.17
1.65
2.00

News Update:


  • Camlin Fine Sciences commences production for manufacture of Hydroquinone & Catechol
    21st Sep 2020, 13:49 PM

    The company has successfully commenced the commercial production for manufacture of Hydroquinone and Catechol on September 21, 2020

    Read More
  • Camlin Fine Sciences’ arm gets dissolved
    17th Sep 2020, 14:15 PM

    The said subsidiary was not a material subsidiary and had ceased to carry any business activity

    Read More
  • Camlin Fine Sciences - Quarterly Results
    10th Aug 2020, 14:07 PM

    Read More
  • Camlin Fine Sciences re-commences trial production at Dahej manufacturing unit
    26th Jun 2020, 11:18 AM

    The company had shut-down manufacturing unit at Dahej which was severely affected due to massive explosion

    Read More
  • Camlin Fine Sciences to raise Rs 1,800 million from funds advised by Convergent Finance LLP
    26th Jun 2020, 09:06 AM

    The purpose of fund raise would be to consolidate and acquire the entire stake of its joint venture partners in the company's subsidiaries in Mexico and China

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.